2021 SAPA Healthcare Investment Forum & Roadshow

Virtual Session
June 25-26, 2021
# Table of Content

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Title Sponsor <strong>Deloitte</strong></td>
</tr>
<tr>
<td>4</td>
<td>2021 SAPA Healthcare Investment Forum &amp; Roadshow: Vision and Mission, Introductions</td>
</tr>
<tr>
<td>7</td>
<td>Organizing Committee</td>
</tr>
<tr>
<td>8</td>
<td>Event Schedule &amp; Agenda</td>
</tr>
<tr>
<td>11</td>
<td>Project List</td>
</tr>
<tr>
<td>13</td>
<td>Project Highlights from the Past Events*</td>
</tr>
<tr>
<td>14</td>
<td>Speakers, Panelists, Investors, and Roadshow Judges</td>
</tr>
<tr>
<td>27</td>
<td>Roadshow Judges</td>
</tr>
<tr>
<td>29</td>
<td>Session Leaders &amp; Moderators</td>
</tr>
<tr>
<td>31</td>
<td>Investors, Corporate BD, and Tech Transfer Offices</td>
</tr>
<tr>
<td>32</td>
<td>Event Sponsors &amp; Strategic Partners</td>
</tr>
<tr>
<td>33</td>
<td>SAPA Corporate Sponsors</td>
</tr>
<tr>
<td>37</td>
<td>Save the Date: Upcoming SAPA Events</td>
</tr>
<tr>
<td>40</td>
<td>SAPA Introduction and Contact Information</td>
</tr>
</tbody>
</table>

* From the previous SAPA Healthcare Investment Forums and Roadshows
The sky is the limit
So, let’s get started

Deloitte’s Life Sciences and Health Care (LSHC) professionals understand the complexity of today’s global industry challenges, and provide clients with integrated, comprehensive services anywhere that they do business. Navigating China’s fast-growing LSHC market as well as US market entry considerations can be challenging, which is why our Chinese Services Group, a network of bilingual professionals working alongside our LSHC industry experts, can make all the difference.

Learn more at www.deloitte.com/healthcare

Copyright © 2021 Deloitte Development LLC. All rights reserved.
• **Vision:**
  To become the premium platform for investors and entrepreneurs in healthcare.

• **Mission:**
  To connect with trusted partners and offer effective solutions and support to emerging enterprises in healthcare.
Aiming to meet the needs of healthcare advancement and bridge break-through science and capital investment, SAPA is planning to host its 4th annual Healthcare Investment Forum and Roadshow to focus on the latest trends and development in the area of healthcare investment. This year’s event will still be held virtually to continue our efforts on this premium flagship event on Friday, June 25 and Saturday, June 26, 2021.

- Promote business cooperation in healthcare and pharmaceutical industry
- Learn the up-to-date trend and outlook of life-science investment
- Discuss and learn how to attract and engage angel investors
- Host roadmap programs where the brightest ideas meet the capital investors
- Utilize 1:1 session meetings and in-depth discussions between the entrepreneur executives and investors
- Join the networking sessions to create more opportunities

We are looking forward to your participation to make it another successful event.
Investment is crucial for companies in life sciences to survive, prosper and bring your innovations to the next stage, especially in this challenging era of COVID-19 Pandemic. Get more funding and stay on the safe side!

Come and join the 2021 SAPA Healthcare Investment Forum and Roadshow!

- Learn the newest trend of investment and development
- Interact with the top investors in life sciences
- Access to a full spectrum of investors from angel fund to late stage investors, as well as BD representatives from biotech and pharma
- 1:1 deep-dive meetings providing opportunities to showcase your project
- Opportunities to out-license your technology and product
- Receive professional review and suggestions for your roadshow materials, and get endorsed by the pharmaceutical veterans at SAPA
- Connect with your peers, share your experience and learning in securing the investments
- Establish connections and open your door to talents, partners and many other resources
- Virtual format with easy remote access and review the forum materials post-meeting
## Organizing Committee of 2021 SAPA Healthcare Investment Forum & Roadshow

### Event Chair and Co-Chairs
- Xiaodong Chen
- Stephen Xue
- Bob Ai

### Committee Members
- Bob Ai
- Yunqi An
- Cythia Cai
- Jiangchao Chen
- Xiaodong Chen
- Gang Cheng
- Haipeng Cheng
- Yvonne Cheng
- Wei Deng
- Chenchao Gao
- Iris Gao
- Andy Han
- May Huang
- Brian Jiang
- Zosia Jiang
- Xue Liang
- Jerry Liu
- Jiajun Mei
- Pan Pan
- Ginny Peng
- Eric Rong
- John Sun
- Mark Tang
- Michelle Tao
- Hui Wang
- Xiaowen Wang
- Hongye Wei
- Jack Wu
- Aiguo Xu
- Stephen Xue
- Xiaojiao Xue
- Yan Yan
- Aming Zhang
- Yulan Zhang
- Yiming Zhao
- Ye Zhou

### Support Team

**WeChat**
- Lan Deng
- Yuantao Li
- Dengpan Liang
- Xiaonan Liu
- Jinqi Zhan

**Zoom**
- Yicong Le
- Yao Liu
- Muyun Xu
- Taoyu Zhu
Event Schedule

Title Sponsor

Deloitte

Wednesday May 26
Business Pitch Bootcamp
8:30 pm – 10:00 pm  How to successfully pitch your business ideas to investors

Saturday June 5
Pre-Roadshow Session I
9:00 pm – 11:00 pm  SAPA investment pre-Roadshow I

Saturday June 12
Pre-Roadshow Session II
9:00 pm – 11:00 pm  SAPA investment pre-Roadshow II

Friday June 25
Roadshow Session
8:00 pm – 11:00 pm  SAPA investment final roadshow

Saturday June 26
Morning Session
Afternoon Session

Friday June 25 – Tuesday June 29
Pre-scheduled Private 1:1 Meetings

All dates and times are in US Eastern Daylight Time (UTC-4).
Friday June 25  
*Roadshow Session*

8:00 pm – 11:00 pm  SAPA Investment Final Roadshow

8:00 pm – 8:10 pm  **Opening Remarks**

8:10 pm – 8:25 pm  Accufusion Therapeutics

8:25 pm – 8:40 pm  Acon Pharmaceuticals

8:40 pm – 8:55 pm  Alephoson Biopharmaceuticals

8:55 pm – 9:10 pm  Chengdu Hyperway Pharmaceuticals

9:10 pm – 9:25 pm  Excellims Corp

9:25 pm – 9:30 pm  **Group photo and session break**

9:30 pm – 9:45 pm  Notitia Biotechnologies Company

9:45 pm – 10:00 pm  Papyrus Therapeutics Inc.

10:00 pm – 10:15 pm  TeamedOn International, Inc.

10:15 pm – 10:30 pm  Vivacitas Oncology Inc.

10:30 pm – 10:45 pm  Zylö Therapeutics

10:45 pm – 10:50 pm  **Sponsor remarks**

10:50 pm – 11:00 pm  Result Announcement & Closing Remarks

*All dates and times are in US Eastern Daylight Time (UTC-4).*
Saturday June 26

Morning Sessions

9:00 am – 12:00 pm  Plenary Session and Fireside Chats

9:00 am – 9:10 am  Opening & SAPA Intro

9:10 am – 9:35 am  Keynote: Recent Trends in Biopharma Industry
                  Umer Raffat, Senior Managing Director, Evercore ISI

9:35 am – 10:00 am  Keynote: The Current Investment Landscape for China Biotech
                    Brad Loncar, CEO, Loncar Investments

10:00 am – 10:25 am  Keynote: The Journey from Bench to IPO
                     Jay Mei, MD, PhD; Founder, Chairman & CEO of Antengene Corporation

10:25 am – 10:35 am  Group Photo, Sponsors’ Presentation Highlights, and Coffee Break

10:35 am – 11:15 am  Fireside Chat 1: IPO Capital Markets Overview and Outlook
                      Danny Wang, Managing Director, Audit & Assurance, Audit Leader, Deloitte US Chinese Services Group, Deloitte & Touche LLP
                      David Yu, Partner, Audit & Assurance LSHC, Deloitte China
                      Rebecca Chan, Partner, Audit & Assurance, Deloitte China

11:15 am – 11:55 am  Fireside Chat 2: Biotech Innovations in China
                      Lucy Lu, CFO, Kintor Pharmaceutical Limited
                      Weimin Tang, PhD, EVP; I-MAB
                      Brad Loncar, CEO, Loncar Investments

11:55 am – 12:00 pm  Closing Remarks

12:00 pm – 1:00 pm  Lunch Break
                    SAPA Events and Sponsors’ Presentation Highlights

All dates and times are in US Eastern Daylight Time (UTC-4).
Saturday June 26

Afternoon Sessions

1:00 pm – 4:30 pm  Entrepreneurship Crash Course

1:00 pm – 1:05 pm  Opening Remarks

1:05 pm – 1:50 pm  An Entrepreneur’s Journey – Start and Build Business in U.S. and China
Shoufeng Li, PhD, CEO and co-founder of Aucta Pharmaceuticals, Inc.

1:50 pm – 2:30 pm  How to Attract Early-Stage Investment
Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Candice He, Director of Pacific Region, Global Investment Strategist, LSN

2:30 pm – 2:40 pm  Group Photo, Sponsors’ Presentation Highlights, and Coffee Break

2:40 pm – 3:00 pm  Startup BD & Licensing In/Out
Lihua Zheng, JD, PhD, Chief Business Officer & Co-Founder, AnHeart Therapeutics

3:00 pm – 3:20 pm  The Fundamentals of Entity Structuring to Maximize Flexibility for Partnering, M&A or IPO
Lillian Li, Managing Director – International Tax, Deloitte Tax LLP
Lynn Yang, Managing Director – Transfer Pricing, Deloitte Tax LLP

3:20 pm – 3:40 pm  An Introduction to the M&A Process
Michael Weiner, Partner of Fox Rothschild

3:40 pm – 4:25 pm  Round Table Clinics Q&A
Panelist:
- All afternoon speakers
- Jerry Liu, PhD, Partner of Fox Rothschild
- Peimin Liu, Senior Manager – International Tax, Deloitte Tax LLP

4:25 pm – 4:30 pm  Closing Remarks

4:45 pm – 5:45 pm  Breakout and Networking Sessions
A: Cross-Border Corporate Structuring: Networking session with Deloitte
B: Key Legal Considerations for Entrepreneurs:
  Networking session with Fox Rothschild
C: Employee Benefit Solutions for Small & Large Business:
  Networking session with United Healthcare
D: Collaboration and Partnership:
  Networking session with AnHeart Therapeutics, Eternity Bioscience, KLUS Pharma, Legend Biotech, and PwC
E: SAPA Roadshow Entrepreneur Alumni Networking Session

All dates and times are in US Eastern Daylight Time (UTC-4).
## Project List

<table>
<thead>
<tr>
<th>Organization Name</th>
<th>Category</th>
<th>Disease area</th>
<th>Development stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alephoson Biopharmaceuticals</td>
<td>Biologics</td>
<td>Ophthalmology</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>B2Med LLC</td>
<td>Small Molecule Pharmaceuticals</td>
<td>Chronic kidney and cardiovascular diseases</td>
<td>Phase I</td>
</tr>
<tr>
<td>Chengdu Hyperway Pharmaceuticals</td>
<td>Small Molecule Pharmaceuticals</td>
<td>Oncology, pain and anti-fungal</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Cipher Surgical Inc</td>
<td>Medical Devices/Diagnostics</td>
<td>Minimally invasive surgery</td>
<td>On market</td>
</tr>
<tr>
<td>Danuvious Biosciences</td>
<td>Medical Devices/Diagnostics</td>
<td>Infection diseases, chronic and neurological diseases</td>
<td>Phase I</td>
</tr>
<tr>
<td>GATTACO Inc</td>
<td>Medical Devices/Diagnostics</td>
<td>Clinical diagnostic testing, especially for blood testing.</td>
<td>Commercial under RUO</td>
</tr>
<tr>
<td>InformDS Technologies</td>
<td>Bioinformatics/software</td>
<td>Clinics Digitisation</td>
<td>On market</td>
</tr>
<tr>
<td>Jinlu Biotechnology</td>
<td>Medical Devices/Diagnostics</td>
<td>Diagnosis assay and testing</td>
<td>Ready for commercialization</td>
</tr>
<tr>
<td>Misum Biotech</td>
<td>Medical Devices/Diagnostics</td>
<td>Companion Diagnostics</td>
<td>On market</td>
</tr>
<tr>
<td>Molecular Theranostics, LLC</td>
<td>Small Molecule Pharmaceuticals</td>
<td>Cancer specific MRI and PET diagnostic imaging drugs</td>
<td>Phase I</td>
</tr>
<tr>
<td>Quantum BioTek Inc.</td>
<td>Bioinformatics/Medical Devices/Diagnostics</td>
<td></td>
<td>Phase III</td>
</tr>
<tr>
<td>Telocyte</td>
<td>Genetics &amp; Genomics</td>
<td>Alzheimer’s disease</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Throne Biotechnologies</td>
<td>Cellular Therapy</td>
<td>Diabetes, alopecia areata, Covid-19, Autoimmune disease</td>
<td>Phase II</td>
</tr>
<tr>
<td>Yiviva</td>
<td>Botanic Medicine</td>
<td>Aging-Associated diseases - including cancer, inflammatory and chronic diseases</td>
<td>Phase II</td>
</tr>
<tr>
<td>Organization Name</td>
<td>Category</td>
<td>Disease area</td>
<td>Development stage</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>AB Biosciences</td>
<td>Biologics</td>
<td>Auto-immune disorders</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Able cerebral, LLC</td>
<td>Medical Device/Diagnosis</td>
<td>All stages of AD, DM and TBI</td>
<td>Phase II</td>
</tr>
<tr>
<td>Accufusion Therapeutics</td>
<td>Biologics</td>
<td>Heart failure for the aging population</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Acon Pharmaceuticals</td>
<td>Nanotechnology/ Drug Delivery/ Formulation</td>
<td>Pulmonary fibrosis; Covid-19</td>
<td>Phase I</td>
</tr>
<tr>
<td>Biopegasus</td>
<td>Medical Device/Diagnosis</td>
<td>Alzheimer’s</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Bloom Standard, Inc</td>
<td>Medical Devices/ Diagnostics</td>
<td>Congenital heart defects, pneumonia, and respiratory diseases</td>
<td>Bench-top testing</td>
</tr>
<tr>
<td>Excellims Corp</td>
<td>Medical Devices/Diagnostics</td>
<td>Mass spectrometers instrumentation</td>
<td>On market</td>
</tr>
<tr>
<td>HbO2 Therapeutics LLC</td>
<td>Biologics</td>
<td>Hematology</td>
<td>Phase III</td>
</tr>
<tr>
<td>Notitia Biotechnologies Company</td>
<td>Microbiome / Bacteriome</td>
<td>Covid-19, Diabetic kidney diseases, Cancer Chemotherapy, Multiple Sclerosis, Parkinson’s disease</td>
<td>Phase I&amp;II</td>
</tr>
<tr>
<td>Papyrus Therapeutics Inc.</td>
<td>Biologics</td>
<td>Oncology</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Sober Grid, Inc.</td>
<td>Software</td>
<td>Substance use disorder</td>
<td>Phase II</td>
</tr>
<tr>
<td>Todos Medical</td>
<td>Medical Device/Diagnosis</td>
<td>Immunology-related</td>
<td>Phase II</td>
</tr>
<tr>
<td>TRIO Pharmaceuticals, Inc.</td>
<td>Biologics</td>
<td>Oncology</td>
<td>Pre-clinical</td>
</tr>
<tr>
<td>Vivacitas Oncology Inc.</td>
<td>Small Molecule Pharmaceuticals</td>
<td>Oncology</td>
<td>Phase II</td>
</tr>
<tr>
<td>Xylyx Bio, Inc.</td>
<td>Advanced biomaterials and disease models for drug discovery</td>
<td>ECM-Related Conditions</td>
<td>On market</td>
</tr>
<tr>
<td>Zylō Therapeutics</td>
<td>Drug Delivery</td>
<td>Erectile Dysfunction, lupus, wound-healing</td>
<td>Pre-clinical</td>
</tr>
</tbody>
</table>
Project Highlights from the Past Events

We have received over 100 projects from different fields in our past roadshow events. Here are a few examples of the participants and their testimonies.

“I attended the 2019 SAPA Healthcare Investment Forum and Roadshow. SAPA Roadshow is a well-established event. It is a good board to meet and get connections.”

Yijun Huang, CEO, Eyekor, Inc., accomplished $20MM Series B funding

“I do enjoy some of your annual meetings which I attended several times. Everybody is doing a great job and contributes their own time and effort. I enjoy the environment, and the organization is quite good.”

Ray Lee, Founder and CMO of Teclison Limited, accomplished $20MM Series A funding

Aimed to harness the intrinsic properties of human cells to convert into different cell types to address critical unmet needs. They are developing specific FOXO1 inhibitors to convert intestinal endocrine cells into glucose-regulated insulin-producing cells in order to treat insulin-dependent diabetes with an oral agent.

Committed to tumor immune cell therapy of high-tech bio technology enterprises. They are making full use of advanced life digitalization technology to stimulate the body’s immune system to fight tumor vitality and develop a new advanced prevention and treatment plan targeting tumor specific antigen, so that patients can benefit from it.

Focusing on genomics and cloud technologies that will accelerate research and discoveries, and enable industrial applications. Their product, Atlas OS, is a cloud operating system for genomics and big data analytics. It is a cloud-computing platform optimized for easy and affordable genomics data analytics and management, with the best built-in civilian data security and privacy protection capabilities.

Focused on developing its patented gene transfer technology into effective treatments for various genetic diseases, infectious diseases, and cancers. Their technology, SimVec, is being employed for developing gene-based therapeutics for human diseases including both inherited and infectious diseases. Current research and development is focused on using this technology to develop human vaccines against HIV, Hepatitis C, Hepatitis B, and SARS.

Their goal is to make in-situ lens cleaning the standard of care by scientifically demonstrating its true value to healthcare systems worldwide. Cipher Surgical has developed the OpClear® a single use, regulated surgical disposable – the only device that cleans the laparoscope lens of all contaminants in situ during a laparoscopic procedure without its removal for cleaning.

A Software-as-a-Service (SaaS) company by providing a first-of-its kind FDA 510(k) cleared data management system with specific indication for use in Ophthalmic Clinical Trials to offer clinical trial stakeholders complete data accessibility and accountability, and consequently enhanced efficiency and accuracy in data collection and interpretation.
Bob Ai, PhD, MBA
Managing Director at Solebury Trout &
Board Member at Edoc Acquisition Corp

At Solebury Trout, Bob focuses on Sino-U.S. cross-border banking, strategic consulting services and investor relations. Prior to joining the firm, Bob was Managing Director, Senior Biotech Analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE listed Chinese specialty pharmaceutical company. He has also served as Principal in the crossover life science private equity firm Merlin Nexus and was Senior Equity Analyst at asset management firms Bennett Lawrence and Merlin Biomed Group. Bob received his Ph.D. and MBA degrees from Penn State University and did postdoctoral training at the University of Pennsylvania. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.

Rebecca Chan
Partner, Audit & Assurance, Deloitte China

Rebecca has over 33 years of experience working with international accounting firms as well as the Hong Kong Exchanges and Clearing Limited where she headed the IPO Transactions Department and the Accounting Affairs Department of their Listing Division. She has been heavily involved in providing accounting and listing rules advice to clients and working on IPOs and post-listing transactions. Rebecca also provided regulatory rules suggestions to various overseas stock exchanges or markets.

She had also acted as a member of the Financial Reporting Advisory Panel of HKEx for the maximum term of six years. Rebecca is also a past member of the Dual Filing Advisory Group of the Securities & Futures Commission of Hong Kong responsible for advising on treatment of cases and policy issues under the dual filing regime for listing in Hong Kong. She is the only accountant by professional training in town who had acted as the Head of IPO Transactions Department in HKEx.

Arranged alphabetically by the last names.
Dennis Ford

Founder & CEO, Life Science Nation (LSN)

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. He has wide-ranging experience in hardware and software computing, middleware, data storage, networking, SaaS, data mining, data profiling, expert systems, and scaling/funding companies. Through Life Science Nation, Dennis has created an ecosystem to streamline early-stage fundraising for next-generation drugs, devices, diagnostics, and digital health products with database subscription services to create business solutions. Dennis has also pioneered a unique global partnering event model that matches buyers and sellers based on their specifically stated needs and declared partnering mandate initiatives garnered from one-on-one interviews and curating buyer/seller databases in a selected industry. The Redefining Early Stage Investments (RESI) conference series creates an interactive dialog between buyers and sellers, which uses data profiling and matching technology to efficiently find that all-important business fit in the marketing and selling process. He is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, and *The Life Science Executive's Fundraising Manifesto*.

Candice He

Pacific Region, Global Investment Strategist
Life Science Nation (LSN)

Candice He is in charge of the business development on the U.S. west coast and sourcing Chinese strategic partners at LSN. She is the lead in expanding the business to the Chinese market and in RESI Shanghai 2019, the first RESI Conference in Asia. She manages relationships with 3,000+ life science companies on the west coast and 800+ Chinese investors, as well as participates in the corporate strategy planning. Before joining LSN, Candice worked for BAC Investments and Bank of New York Mellon. Candice has extensive networks in both the US and China of life science and technology industry. She got a master’s degree in finance from Brandeis University in Boston and went to college at Southwestern University of Finance and Economics in Chengdu, China.
Seamus Jiang, MBA
Managing Director, PwC

Seamus is a Deals Managing Director of PwC US based in New York and Philadelphia with over 20 years of M&A and finance experience in North America and Asia. He has been assisting strategic and financial buyers/sellers in evaluating over 200 M&A and investment transactions with an aggregate deal value of over $200 billion in a variety of industries including many M&A and capital market projects in the Pharma and Life Sciences sector. Seamus also leads the overall U.S./China Cross-border Deals practice. In recent years, he has led over 60 U.S./China cross-border M&A and investment projects spanning across pre-deal strategy, due diligence execution and post-deal integration and value capture. Seamus earned a B.A. in International Economics from Fudan University and an M.B.A. from Goizueta Business School of Emory University. He is a CFA charterholder and holds CPA licenses in both U.S. and China.

Lillian Li
Managing Director – International Tax
Deloitte Tax LLP

Lillian has 20 years’ professional experience in the international tax area. Lillian assists multi-national clients with tax advantaged investment structuring, financing, strategies, repatriation techniques, international tax reporting and global tax minimization. She leads the international tax service teams of some of Deloitte’s largest clients, including several large asset management firms and financial institutions. She is a trusted advisor and has in-depth knowledge in analyzing the issues and opportunities relevant to investment funds, fund organizers, fund investors and their investment portfolios.

Lillian is also a leader in Deloitte’s Chinese inbound tax services. She has extensive experience working with Chinese executives and assisting Chinese entities doing business in the US, especially with entrepreneurs in life sciences & health care industry. Lillian is very knowledgeable in intangible property planning, IPO positioning, and cross-border M&A.

Lillian is a member of the New York State Bar Association. She graduated from Fudan University and received her LL.M. degree from New York University School of Law.
Shoufeng Li, PhD
CEO at Aucta Pharmaceuticals, Inc.

Dr. Shoufeng Li is CEO and co-founder of Aucta Pharmaceuticals, Inc, a technology-based company creating better products of proven molecules using 505(b)(2) regulatory pathway and focusing on the development and commercialization of Branded Specialty Products. Prior to founding Aucta Pharmaceuticals, Dr. Li is Director, Technical Project Leader at Novartis Pharmaceuticals Corporation at East Hanover, NJ, where he was managing a multidisciplinary project teams, he was responsible for late phase project management and represent CMC function in global project team (GPT). Dr. Li has over 15 years of multi-national industrial product development experience in both small molecule and peptide/proteins delivery.

Dr. Li’s interest and area of expertise is in 505(b)(2) product development and in vitro - in vivo correlation, he has been instrumental in overcoming multiple difficult to formulate bioequivalent products during his tenure at Novartis and was awarded Novartis Leading Scientist in 2007. He has been invited speakers in international forum for multiple occasions, and has over 30 peer reviewed research articles, reviews and patents. Dr. Li holds Ph.D. in Pharmaceutics and M.S. in Statistics from Rutgers University. He has been actively involved professionally in AAPS, SAPA and BayHelix.

Wansheng Jerry Liu, PhD, JD
Partner and Chair of China Practice, Fox Rothschild LLP

Jerry Liu is a Partner and the Chair of China Practice Group of Fox Rothschild LLP, a 950-lawyer U.S. law firm. Jerry practices in wide areas of intellectual property and corporate laws and serves clients from individuals and start-up companies to Fortune 500 companies in their IP protection, formation of business entities, contract negotiations, and so on, including investment and licensing deals valued from multi-million to multi-billion dollars. The China Practice Group he chairs is comprised of over 30 attorneys nationwide in many areas of laws.

Jerry previously worked as a process chemist at Bristol-Myers Squibb. He obtained Ph.D. in Organic Chemistry with Professor Sir Derek Barton (Nobel Prize, 1969) from Texas A&M University, J.D. from Rutgers University School of Law, and B.S./M.S. from Chemistry/Polymer Science from University of Science and Technology of China (USTC).

Jerry served as the Editor-in-Chief of Rutgers Law Record and SAPA President (2019-2020) and is serving as Co-Chair of the CNIPA Committee of the New York Intellectual Property Law Association (NYIPLA) and General Counsel of the USTC Alumni Association of Greater New York. A frequent speaker on IP laws and FDA regulations, Jerry has over 20 scientific or legal publications and U.S. patents.

Arranged alphabetically by the last names.
Jian Liu, PhD

Chief Scientific Officer and Site Head
Eternity Bioscience Inc.

Dr. Jian Liu is currently the chief scientific officer and site head at Eternity Bioscience Inc., the Hengrui Medicine Group US R&D center located in Cranbury New Jersey, in charge of the site operation and drug innovation for oncology, immunology and neuro degenerative diseases. Dr. Liu obtained a Ph.D. degree in organic and computational chemistry from UCLA. He joined the medicinal chemistry department in Merck Research Laboratory at Rahway site in February 2001. Dr. Liu has worked on and managed projects from target validation, lead identification, and lead optimization to generate multiple preclinical candidates which went to first in human, phase I, phase II clinic trials. Dr. Liu is an expert in drug discovery for many therapeutic areas such as osteoporosis, obesity, diabetes, cardiovascular disease, rheumatoid arthritis, oncology and immunology, pain, and infection disease. Based on his research work, Dr. Liu has published over 100 peer reviewed papers, patents, and patent applications. Dr. Liu volunteered as an Executive Council member of Sino-American Pharmaceutical Professionals Association (SAPA) and was the SAPA 25th president in 2018. He is currently a board of director member of SAPA. Dr. Liu was honored as the 2019 Outstanding 50 Asian American in Business awardee in New York City.

Peimin Liu

Senior Manager – International Tax, Deloitte Tax LLP

Peimin is a senior international tax manager with over ten years of US and international tax experience in consulting and compliance services for clients in cross border transactions between US and Asia. She is experienced in advising US multinational companies investing in Asia as well as Chinese companies investing in the U.S. She was a member of the Deloitte Asia Pacific International Core of Excellence (AP ICE) based in Hong Kong between 2015-2019.

She is also experienced in assisting clients with their cross-border wealth management and tax planning. She has strong technical expertise in business and individual taxation with diversified experience in all major tax areas. She serves domestic and international, public and middle market companies, as well as family office clients.
Brad Loncar

CEO, Loncar Investments

Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of the Loncar China BioPharma Index. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at LoncarBlog, Nasdaq.com, and contributes opinion pieces to Endpoints News.

Lucy Lu

CFO of Kintor Pharmaceutical Limited

Ms. Lucy Lu was appointed as the Chief Financial Officer of Kintor Pharmaceutical Limited in December 2019. Ms. Lu is primarily responsible for financial planning, internal control, investor relations and public relations of Kintor. Prior to joining Kintor, Ms. Lu has over 13 years of experience in investment banking business. Ms. Lu joined GF Capital (Hong Kong) Limited in July 2018 with her last position as the director, head of investment banking business and managing director. From September 2007 to July 2018, Ms. Lu worked at UBS Securities Hong Kong Limited with her last position as an executive director in the Asian healthcare group. She has been a signing Principal for Hong Kong sponsorship IPOs since 2014, when she worked in UBS. From August 2006 to August 2007, Ms. Lu worked at Credit Suisse (Hong Kong) Limited as an analyst. Ms. Lu obtained her bachelor’s degree in finance from School of Finance in Renmin University of China in the PRC in July 2003, and her master’s degree in finance from Guanghua School of Management in Peking University in the PRC in July 2005.
Jay Mei, MD, PhD

Founder, Chairman & CEO of Antengene Corporation

Dr. Mei founded Antengene in 2017, which has since become one of the leading biotech companies based in China and APAC with strong drug discovery and clinical development expertise and operational capabilities. Antengene Corporation became listed in HKEx in November 2020 (SEHK: 6996.HK). Currently, Antengene is conducting multiple clinical trials in China and other APAC countries/regions, including two registration studies. The first commercial launch of Antengene’s lead pipeline product in China and APAC is expected in 2021-2022. Antengene has entered into strategic partnership with Celgene (now BMS), AstraZeneca and Karyopharm Therapeutics over the past three years.

Prior to founding Antengene, Dr. Mei served multiple senior roles in clinical development at Celgene, Novartis and Johnson & Johnson. Dr. Mei was one of the leading members in the clinical development of multiple blockbuster drugs including REVLIMID®, which is among the best-selling oncology therapies worldwide. Dr. Mei was also involved in the clinical development of POMALYST®, another one of the best-selling oncology drugs worldwide, and IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia (AML).

Dr. Mei received his M.D. degree from Xiang-Ya School of Medicine and obtained his Ph.D. degree in pharmacology and toxicology from the University of Maryland. Dr. Mei also serves as the Adjunct Professor at Blumberg Institute. Dr. Mei is the author of over 70 publications and holds multiple patents. Dr. Mei is also a member of many professional associations and industry organizations, such as ASCO, ASH, SAPA, USCACA, etc.

Umer Raffat

Senior Managing Director Evercore ISI

Umer Raffat is a Senior Managing Director at Evercore ISI and heads our large cap therapeutics effort spanning Biotech, Pharmaceuticals-major and Specialty Pharmaceuticals.

Umer has been ranked #1 on twelve separate occasions by Institutional Investor, starting from his very first year covering the sector. He currently ranks #1 across all three sectors he covers: biotech, pharma-major and pharma-specialty. Previously, he ranked #1 Rising Star Analyst for two years in a row.

Umer started his equity research career under Dr. Mark Schoenebaum at Deutsche Bank in 2010, and they moved together to Evercore ISI. Umer has an undergrad in biology from University of Texas at Arlington and a Masters from Harvard School of Public Health. In 2020, Umer was inducted into Hall of Fame by Institutional Investor All America Research Team, a designation for analysts who have earned a No. 1 ranking ten times or more.
Weimin Tang, PhD  
EVP, I-MAB

Dr. Weimin Tang is currently EVP of I-MAB Biopharma, a clinical stage biotech company focus on Immunology and Oncology. He served as Interim CEO/Head of US Business Development, Jiangsu Hengrui Medicine previously and build Hengrui global business development team and clinical operation in Princeton, NJ. He was trained as cancer biologist with PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and Biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management. Dr. Tang received his Bachelor’s Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences.

Daniel Tu, PhD  
Director of Business Development, Legend Biotech

Daniel Tu is Director of Business Development at Legend Biotech. Prior to join Legend in 2017, he served several scientific and commercial roles at GenScript since 2011, including Director, Head of Corporate Development of SMAB Bispecific Antibody Platform, Head of Global Commercial Team of Discovery Biology Business Unit, Scientific Liaison of US Eastern Region and Senior Scientist of Antibody Department. He received his PhD of Immunology from joint training of Case Western Reserve University/ West China Hospital of Sichuan University, and bachelor’s degree of Biotechnology from Life Science College of Sichuan University.
Danny Wang
Managing Director, Audit & Assurance
Audit Leader, Deloitte US Chinese Services Group
Deloitte & Touche LLP

Danny has over 20 years of experience in the financial services industry, where he has led a number of audits of SEC registrants, broker and dealers in securities and investment advisors. Danny’s focus is primarily on global audit coordination and execution, SEC reporting and a variety of technical accounting topics.

Michael Weiner, JD
Partner, Fox Rothschild LLP

Corporate attorney with 40 years’ experience representing early, middle and later stage companies in a broad range of industries, including technology and life science. Particular focus on capital formation, mergers, acquisitions and divestitures.
Lynn Yang
Managing Director – Transfer Pricing
Deloitte Tax LLP

With over 20 years of economic consulting and Big 4 experiences, Lynn specializes in assisting clients with global tax rationalization, transfer pricing planning, documentation, and audit defense. Lynn has been with Deloitte Tax LLP for fourteen years.

Lynn has extensive experiences in leading and conducting transfer pricing analyses related to intercompany services, supply chain alignment, intangible property transfer, cost sharing arrangements, tangible goods transfer, and intercompany financing. Lynn’s work has spanned a variety of industries, including pharmaceuticals, chemicals, financial services, commercial and residential real property, investment advice, and many other sectors.

Lynn is also the transfer pricing leader of Deloitte’s US Chinese Services Group. Lynn has served numerous Chinese inbound clients to meet their transfer pricing needs. Lynn also assumes the lead client service or lead tax service role for several large Chinese clients.


Lynn received her Ph.D. in economics from University of Colorado - Boulder and her MA and BA in Economics from People’s (Renmin) University of China.

David Yu
Partner, Audit & Assurance LSHC
Deloitte China

David Yu is deputy audit leader of Deloitte Eastern China region. He is also the life science healthcare industry leader in audit function. David has been an Audit Partner of Deloitte China since 2011 and has extensive experience in auditing companies listed in the U.S. and the China stock markets. He started his career of Deloitte in Shanghai office and had a two-year working experience in New York office of Deloitte U.S. firm from 2004 to 2006, then returned to Shanghai. David focuses on U.S. Generally Accepted Accounting Principles and reporting matters related to U.S. Securities & Exchange Commission. He has sound experience in leading teams to serve local and multinational clients.
Yiwei Zhang, MD, PhD

CEO of KLUS Pharma

Dr. Yiwei Zhang is the VP of Sichuan Kelun Pharmaceutical Research Institute, CMC Head of Sichuan Kelun-Biotech, and CEO of KLUS Pharma. As early as 1984-1990, while at the Sichuan Academy of Medical Sciences, he engaged in scientific research projects, the results of which was granted the Third Prize of Science and Technology Progress of Sichuan Province. After graduating from PhD work at the University of Leeds in England, he served as a post-doctoral researcher and associate researcher at the Albert Einstein College of Medicine in New York from 1995 to 2007. He became involved in research that looked at the biochemistry and molecular biology of AIDS-associated infectious diseases. In 2007 he started working in biopharmaceuticals, and from 2007 to 2017 he served as a QC scientist and senior scientist at Imclone Systems Inc. and Eli Lilly and Company. In January 2018 he joined Kelun-Biotech as QC Director and became Deputy Head of Quality Unit, and VP of Kelun Pharmaceutical Research Institute. Dr. Yiwei Zhang has published 22 significant papers in both domestic and international research journals and his work appears in chapters elsewhere.

Lihua Zheng, JD, PhD

Co-Founder & Chief Business Officer
AnHeart Therapeutics Inc. LLP

Dr. Zheng is both an entrepreneur and a seasoned business advisor with extensive knowledge of technical, business and legal nature. He is particularly experienced in transactions for life sciences companies and has guided transactions valued in total several hundred million dollars in the past few years. Previously he founded and led a boutique New York law firm specialized in venture financing and intellectual property transactions. He started his legal career in a wall street international law firm where he assisted major investment banks with matters relating to public offerings by many biotechnology issuers on NASDAQ and emerging growth companies with their IP and general corporate matters.

Dr. Zheng graduated from Fordham University School of Law with Juris Doctor and from Baylor College of Medicine with PhD in Molecular and Human Genetics. He obtained Master of Science and Bachelor of Science both from Fudan University. He is licensed to practice law in the State of New York and at the United States Patent and Trademark Office.

Arranged alphabetically by the last names.
Lili Zheng is a senior US international tax partner at Deloitte with more than 30 years of cross-border tax planning experience. Leveraging on her extensive experience in Deloitte offices in San Francisco, Tokyo, Beijing, San Jose and Hong Kong, Ms. Zheng provides practical and implementable solutions to clients regarding their greenfield investment in the US, M&A, and cross-border investment entry and exit strategies. She also offers comprehensive support to US companies aiming to enter the Greater China region.

She is a trusted advisor with substantial experience in advising PE/VC funds and their portfolio companies in IPO positioning & IP planning to access different capital markets globally. Especially, the years of experience working in Silicon Valley enables her to provide tailored advices to start-ups at different growing stages. Ms. Zheng has serviced clients from various industries, including life science & healthcare, financial services, manufacturing, and technology.

Fluent in Mandarin and Cantonese, Ms. Zheng has a deep understanding of the unique considerations of companies from Asia Pacific and has been a frequent speaker at different events and platforms, including SelectUSA and BIO.

Ms. Zheng received her B.S., Accounting and Finance from UC Berkeley and M.S. in Taxation from Golden Gate University.
Roadshow Judges

Bob Ai, PhD, MBA
Managing Director at Solebury Trout & Board Member at Edoc Acquisition Corp

Daqing (Darren) Cai, PhD
Founder & Managing Partner Sherpa Healthcare Partners

Cynthia Cai, PhD, MBA, M. Eng.
President, Tharton Consulting Venture Partner, Viva BioInnovator

Yang Huang, PhD
Director, China Healthcare Research Credit Suisse

Praveen Kudithipudi, MD, MBA
Director of Business Development Otsuka Pharma

Arranged alphabetically by the last names.
James Lee, PhD
Principal, Oncology Lead
Cello Health BioConsulting

Yaping Shou, MD, PhD
Venture Partner
Lilly Asia Ventures

Mark Tang, PhD, MBA
Partner
Good Health Capital, New York

Chong Xu, PhD
Principal at F-Prime Capital

Mark Young, MBA
Co-Founder and Chief Investment Officer
L Catterton

Arranged alphabetically by the last names.
Session Leaders & Moderators

Bob Ai, PhD, MBA
Managing Director at Solebury Trout & Board Member at Edoc Acquisition Corp

Xiaodong Chen, PhD
SAPA President-elect Director of CMC Operations, Roivant Sciences

Chenchao Gao, PhD
Manager, Alliance Team and Regulatory Strategy Daiichi Sankyo

May Huang
Senior Manager Taiho Oncology

Jiajun Mei, PhD
Associate Director, Aleon Pharma International

Arranged alphabetically by the last names.
Pan Pan, PhD
Business Development Director
KLUS Pharma

Eric Rong
President
Praxgen Pharmaceuticals

John Sun, PhD, MBA
President, SAPA
Global Program Lead, Novartis

Xiaowen Wang, PhD
Senior Scientist
Biologics Upstream Process Research and Development
Merck & Co.

Stephen Xue
Director of Operation
Chipscreen Bioscience (US) Ltd

Arranged alphabetically by the last names.
Part of Participating Investors
Event Sponsors

Title Sponsor
Deloitte.

General Sponsors

Strategic Partners

bioVILLAGE
WWC Professional Corporation Limited, CPA
J.P. Morgan

BIOCENTURY
BRIDGE
BioNJ
LIFE SCIENCE NATION
2020-2021
SAPA Corporate Sponsors

[Image showing logos of various sponsors]
杭州湾生命科技园BioVillage

位于宁波前湾新区高端产业区核心地块。园区占地100亩，规划总建筑面积约7万平方米，由生物医药创业孵化楼、企业独栋等组成。2020年12月，园区一期约3.5万平方米正式投用，包含一栋2万平方米孵化楼和两栋各7500平方米企业独栋。BioVillage由宁波康汇科技发展有限公司建设并运营，是国内为数不多的民营企业主导开发的生物医药专业园区之一。

通过与龙化成的紧密合作，以VC模式（VC+IP+CRO）为主导，辅以专业、高效而精准的服务，赋能Biotech公司，为打造生物医药生态圈贡献绵薄之力。

园区地址：宁波杭州湾新区启源路39号

联系人：Sarah Feng 13917002533（微信同号） Ella Shen 13857885089（微信aila0329） Devin Yang 18521323662（微信同号）
JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.7 trillion and operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of customers in the United States and many of the world’s most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands.
SAPA Career Talk 8@8 is a virtual webinar series hosted on the 8th day of every month at 8 pm. We will discuss career hot topics and address concerns interested to SAPA members and friends. These sessions are complimentary to all.

https://sapaweb.org
Elevating Leadership Capabilities

Virtual Session
July 31, 2021

https://sapaweb.org
2021
SAPA Annual Conference

October 1 – 2, 2021
DoubleTree by Hilton
Somerset Hotel and
Conference Center
Somerset, NJ 08873
USA

Science
Education
Collaboration
Career

https://sapaweb.org
The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA. Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA's members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries, and promote entrepreneurship, healthcare investment and business cooperation.

As a non-profit organization registered in the US, SAPA receives generous sponsorship and support from numerous multinational companies in the US and overseas. SAPA will continue to provide a broad platform for scientific and technical discussion, talent exchange, collaboration and cooperation, and training for the colleagues in the pharmaceutical industry from the US and China.

SAPA Sites and Chapters

- SAPA-HQ (Headquarter): New Jersey, USA
- SAPA-NE (New England Chapter): Boston and New England region, USA
- SAPA-GP (Greater Philadelphia Chapter): Philadelphia and other Pennsylvania areas, USA
- SAPA-MW (Mid-West Chapter): Illinois and Indiana, USA
- SAPA-CT (Connecticut Chapter): Connecticut, USA
- SAPA-DC (DC Chapter): District of Columbia and Maryland, USA
- SAPA-China: Zhengzhou and Beijing, China

Professional Expertise of SAPA Members

- Drug discovery, research and development
- Preclinical and clinical research and development
- Application and registration of new drug and biologics to the US FDA
- Production and manufacture of pharmaceuticals and biological products
- Commercial and marketing of pharmaceutical and biological products
- Generic product development and technology
SAPA Mission:

As a global organization, SAPA's mission is:

- To promote the advancement of pharmaceutical science and biotechnology
- To contribute to public health education
- To promote entrepreneurship, healthcare investment and business cooperation
- To foster the career growth of pharmaceutical professionals

Follow SAPA on:
LinkedIn: SAPA-HQ
WeChat: SAPA-HQ

https://sapaweb.org